nach oben

Inflammopharmacology

Erschienen in:

01.02.2023 | COVID-19 | Review

The direct correlation between microbiota and SARS-CoV-2 infectious disease

verfasst von: Antonio Vitiello, Francesco Ferrara, Andrea Zovi

Erschienen in: Inflammopharmacology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

The human microbiota is the good part of the human organism and is a collection of symbiotic microorganisms which aid in human physiological functions. Diseases that can be generated by an altered microbiota are continuously being studied, but it is quite evident how a damaged microbiota is involved in chronic inflammatory diseases, psychiatric diseases, and some bacterial or viral infections. However, the role of the microbiota in the host immune response to bacterial and viral infections is still not entirely understood. Metabolites or components which are produced by the microbiota are useful in mediating microbiota–host interactions, thus influencing the host’s immune capacity. Recent evidence shows that the microbiota is evidently altered in patients with viral infections such as post-acute COVID-19 syndrome (PACS). In this review, the associations between microbiota and COVID-19 infection are highlighted in terms of biological and clinical significance by emphasizing the mechanisms through which metabolites produced by the microbiota modulate immune responses to COVID-19 infection.

Andoh A (2016) Physiological Role of Gut Microbiota for Maintaining Human Health. Digestion 93(3):176–181. https://doi.org/10.1159/000444066CrossRefPubMed

Arpaia N, Campbell C, Far X et al (2013) Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504:451–455. https://doi.org/10.1038/nature12726CrossRefPubMedPubMedCentral

Belkaid Y, Hand TW (2014) Role of the microbiota in immunity and inflammation. Cell 157(1):121–141. https://doi.org/10.1016/j.cell.2014.03.011CrossRefPubMedPubMedCentral

Bevins CL, Salzman NH (2011) Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol 9:356–368. https://doi.org/10.1038/nrmicro2546CrossRefPubMed

Cash HL, Whitham CV, Behrendt CL et al (2006) Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science 313:1126–1130. https://doi.org/10.1126/science.1127119CrossRefPubMedPubMedCentral

Chen J, Hall S, Vitetta L (2021) Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. Rev Med Virol 31(5):1–13. https://doi.org/10.1002/rmv.2211CrossRefPubMed

Collins MD, Gibson GR (1999) Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 69:1052S-1057SCrossRefPubMed

DeGruttola AK, Low D, Mizoguchi A et al (2016) Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis 22(5):1137–1150. https://doi.org/10.1097/MIB.0000000000000750CrossRefPubMed

Ferrara F (2020) Antirheumatic in SARS-CoV-2: benefit or risk? Italian J Me 14(2):114–115. https://doi.org/10.4081/itjm.2020.1290CrossRef

Ferrara F, Vitiello A (2021) Scientific hypothesis for treatment of COVID-19’s lung lesions by adjusting ACE/ACE2 Imbalance. Cardiovasc Toxicol 21(6):498–503. https://doi.org/10.1007/s12012-021-09649-yCrossRefPubMedPubMedCentral

Ferrara F, Porta R, D’Aiuto V et al (2021) Remdesivir and COVID-19. Ir J Med Sci 190(3):1237–1238. https://doi.org/10.1007/s11845-020-02401-5CrossRefPubMed

Fischer DD, Kandasamy S, Paim FC et al (2017) Protein malnutrition alters tryptophan and angiotensin-converting enzyme 2 homeostasis and adaptive immune responses in human rotavirus-infected gnotobiotic pigs with human infant fecal microbiota transplant. Clin Vaccin Immunol 24(8):e00172-e217CrossRef

Furusawa Y, Obata Y, Fukuda S et al (2013) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504:446–450. https://doi.org/10.1038/nature12721CrossRefPubMed

Gallo RL, Hooper LV (2012) Epithelial antimicrobial defence of the skin and intestine. Nat Rev Immunol 12:503–516. https://doi.org/10.1038/nri3228CrossRefPubMedPubMedCentral

Gallo A, Passaro G, Gasbarrini A et al (2016) Modulation of microbiota as treatment for intestinal inflammatory disorders: an uptodate. World J Gastroenterol 22:7186–7202CrossRefPubMedPubMedCentral

Gesesew HA, Koye DN, Fetene DM, Woldegiorgis M, Kinfu Y, Geleto AB, Melaku YA, Mohammed H, Alene KA, Awoke MA, Birhanu MM, Gebremedhin AT, Gelaw YA, Shifti DM, Muluneh MD, Tegegne TK, Abrha S, Aregay AF, Ayalew MB, Gebre AK, Gebremariam KT, Gebremedhin T, Gebremichael L, Leshargie CT, Kibret GD, Meazaw MW, Mekonnen AB, Tekle DY, Tesema AG, Tesfay FH, Tesfaye W, Wubishet BL, Dachew BA, Adane AA (2021) Risk factors for COVID-19 infection, disease severity and related deaths in Africa: a systematic review. BMJ Open 11(2):e044618. https://doi.org/10.1136/bmjopen-2020-044618CrossRefPubMed

Gilbert JA, Blaser MJ, Caporaso JG et al (2018) Current understanding of the human microbiome. Nat Med 24(4):392–400. https://doi.org/10.1038/nm.4517CrossRefPubMedPubMedCentral

Gu S, Chen Y, Wu Z et al (2020) Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza. Clin Infect Dis 71(10):2669–2678. https://doi.org/10.1093/cid/ciaa709CrossRefPubMed

Hansson GC (2020) Mucins and the microbiome. Annu Rev Biochem 20(89):769–793. https://doi.org/10.1146/annurev-biochem-011520-105053CrossRef

Hao Q, Dong BR, Wu T. (2015) Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev CD006895

Hooper LV, Stappenbeck TS, Hong CV et al (2003) Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat Immunol 4:269–273. https://doi.org/10.1038/ni888CrossRefPubMed

Hryckowian AJ, Van Treuren W, Smits SA et al (2018) Microbiota-accessible carbohydrates suppress Clostridium difcile infection in a murine model. Nat Microbiol 3(6):662–669. https://doi.org/10.1038/s41564-018-0150-6CrossRefPubMedPubMedCentral

Ke S, Weiss ST, Liu YY (2022) Dissecting the role of the human microbiome in COVID-19 via metagenome-assembled genomes. Nat Commun 13(1):5235. https://doi.org/10.1038/s41467-022-32991-wCrossRefPubMedPubMedCentral

Keely S, Talley NJ, Hansbro PM (2012) Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol 5(1):7–18. https://doi.org/10.1038/mi.2011.55CrossRefPubMed

Klemashevich C, Wu C, Howsmon D et al (2014) Rational identification of diet-derived postbiotics for improving intestinal microbiota function. Curr Opin Biotechnol 26:85–90CrossRefPubMed

Kotzampassi K, Stavrou G, Damoraki G et al (2015) A four-probiotics regimen reduces postoperative complications after colorectal surgery: a randomized, double-blind, placebo-controlled study. World J Surg 39:2776–2783CrossRefPubMed

Lotz MT, Peebles RS (2012) Mechanisms of respiratory syncytial virus modulation of airway immune responses. Curr Allergy Asthma Rep 12(5):380–387. https://doi.org/10.1007/s11882-012-0278-zCrossRefPubMedPubMedCentral

Lu Y, Yuan X, Wang M, He Z, Li H, Wang J, Li Q (2022) Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J Hematol Oncol 15(1):47. https://doi.org/10.1186/s13045-022-01273-9CrossRefPubMedPubMedCentral

Macfarlane GT, Macfarlane S (1997) Human colonic microbiota: ecology, physiology and metabolic potential of intestinal bacteria. Scand J Gastroenterol Suppl 222:3–9. https://doi.org/10.1080/00365521.1997.11720708CrossRefPubMed

Mazzarelli A, Giancola ML, Farina A et al (2021) 16S rRNA gene sequencing of rectal swab in patients affected by COVID-19. PLoS One. 16(2):e0247041. https://doi.org/10.1371/journal.pone.0247041CrossRefPubMedPubMedCentral

Nagata N, Takeuchi T, Masuoka H et al (2022) Human Gut Microbiota and Its Metabolites Impact Immune Responses in COVID-19 and Its Complications. Gastroenterology S0016–5085(22):01081–01082. https://doi.org/10.1053/j.gastro.2022.09.024CrossRef

Ojeda P, Bobe A, Dolan K et al (2016) Nutritional modulation of gut microbiota - the impact on metabolic disease pathophysiology. J Nutr Biochem 28:191–200CrossRefPubMed

Olaimat AN, Aolymat I, Al-Holy M, Ayyash M, Abu Ghoush M, Al-Nabulsi AA, Osaili T, Apostolopoulos V, Liu SQ, Shah NP (2020) The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19. NPJ Sci Food 5(4):17. https://doi.org/10.1038/s41538-020-00078-9CrossRef

Schuijt TJ, Lankelma JM, Scicluna BP et al (2016) The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut 65(4):575–583. https://doi.org/10.1136/gutjnl-2015-309728CrossRefPubMed

Segers ME, Lebeer S (2014) Towards a better understanding of lactobacillus rhamnosus GG-host interactions. Microb Cell Fact 13(Suppl 1):S7CrossRefPubMedPubMedCentral

Selsted ME, Ouellette AJ (2005) Mammalian defensins in the antimicrobial immune response. Nat Immunol 6:551–557. https://doi.org/10.1038/ni1206CrossRefPubMed

Sencio V, Barthelemy A, Tavares LP et al (2020) Gut dysbiosis during influenza contributes to pulmonary pneumococcal superinfection through altered short-chain fatty acid production. Cell Rep 30(9):2934-2947.e6. https://doi.org/10.1016/j.celrep.2020.02.013CrossRefPubMed

Smith TJ, Rigassio-Radler D, Denmark R et al (2013) Effect of lactobacillus rhamnosus LGG® and Bifidobacterium animalis ssp. lactis BB-12® on health-related quality of life in college students affected by upper respiratory infections. Br J Nutr 109(11):1999–2007CrossRefPubMed

Ursell LK, Metcalf JL, Parfrey LW et al (2012) Defining the human microbiome. Nutr Rev. https://doi.org/10.1111/j.1753-4887.2012.00493.x. (Suppl 1(Suppl 1):S38-44)CrossRefPubMed

van Nood E, Vrieze A, Nieuwdorp M et al (2013) Duodenal infusion of donor feces for recurrent clostridium difficile. N Engl J Med 368:407–415CrossRefPubMed

Veiga P, Suez J, Derrien M, Elinav E (2020) Moving from probiotics to precision probiotics. Nat Microbiol 5(7):878–880. https://doi.org/10.1038/s41564-020-0721-1CrossRefPubMed

Venzon M, Bernard-Raichon L, Klein J et al. (2021) Gut microbiome dysbiosis during COVID-19 is associated with increased risk for bacteremia and microbial translocation. https://doi.org/10.21203/rs.3.rs-726620/v1.

Vitiello A, La Porta R, Ferrara F (2021) Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses. https://doi.org/10.1016/j.mehy.2021.110486CrossRefPubMedPubMedCentral

Vitiello A, Pelliccia C, Ferrara F (2021) Drugs acting on the renin-angiotensin system and SARS-CoV-2. Drug Discov Today 26(4):870–874. https://doi.org/10.1016/j.drudis.2021.01.010CrossRefPubMedPubMedCentral

Vitiello A, Ferrara F, Auti AM et al (2022) Advances in the Omicron variant development. J Intern Med 292(1):81–90. https://doi.org/10.1111/joim.13478CrossRefPubMedPubMedCentral

Vitiello A, Porta R, Pianesi L, Ferrara F (2022) COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. Ir J Med Sci 191(1):487–488. https://doi.org/10.1007/s11845-021-02584-5CrossRefPubMed

Waldman AJ, Balskus EP (2018) The human microbiota, infectious disease, and global health: challenges and opportunities. ACS Infect Dis 4(1):14–26. https://doi.org/10.1021/acsinfecdis.7b00232CrossRefPubMed

Wijburg OL, Uren TK, Simpfendorfer K et al (2006) Innate secretory antibodies protect against natural Salmonella typhimurium infection. J Exp Med 203(1):21–26. https://doi.org/10.1084/jem.20052093CrossRefPubMedPubMedCentral

Wu HJ, Wu E (2012) The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. https://doi.org/10.4161/gmic.19320CrossRefPubMedPubMedCentral

Xu R, Lu R, Zhang T et al (2021) Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults. Commun Biol 4(1):240. https://doi.org/10.1038/s42003-021-01796-wCrossRefPubMedPubMedCentral

Xu AA, Kennedy LK, Hoffman K et al (2022) Dietary Fatty Acid Intake and the Colonic Gut Microbiota in Humans. Nutrients 14(13):2722. https://doi.org/10.3390/nu14132722CrossRefPubMedPubMedCentral

Yang Y, Palm NW (2020) Immunoglobulin A and the microbiome. Curr Opin Microbiol 56:89–96. https://doi.org/10.1016/j.mib.2020.08.003CrossRefPubMed

Yazar A, Atis S, Konca K et al (2001) Respiratory symptoms and pulmonary functional changes in patients with irritable bowel syndrome. Am J Gastroenterol 96(5):1511–1516. https://doi.org/10.1111/j.1572-0241.2001.03748.xCrossRefPubMed

Yeoh YK, Zuo T, Lui GC-Y et al (2021) Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. https://doi.org/10.1136/gutjnl-2020-323020CrossRefPubMed

Zhang F, Wan Y, Zuo T et al (2022) Prolonged impairment of short-chain fatty acid and L-isoleucine biosynthesis in gut microbiome in patients with COVID-19. Gastroenterology 162(2):548-561.e4. https://doi.org/10.1053/j.gastro.2021.10.013CrossRefPubMed

Zhao Y, Chen F, Wu W et al (2018) GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3. Mucosal Immunol 11(3):752–762. https://doi.org/10.1038/mi.2017.118CrossRefPubMedPubMedCentral

Zuo T, Wu X, Wen W, Lan P (2021) Gut microbiome alterations in COVID-19. Genomics Proteomics Bioinformatics 19(5):679–688. https://doi.org/10.1016/j.gpb.2021.09.004CrossRefPubMedPubMedCentral

Titel: The direct correlation between microbiota and SARS-CoV-2 infectious disease
verfasst von: Antonio Vitiello
Francesco Ferrara
Andrea Zovi
Publikationsdatum: 01.02.2023
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Inflammopharmacology / Ausgabe 2/2023
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-023-01145-9

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Antioxidants: an approach for restricting oxidative stress induced neurodegeneration in Alzheimer’s disease

Intramuscular compatibility of an injectable anti-inflammatory nanodispersion from a standardized Bixa orellana oil (Chronic®): a toxicological study in Wistar rats

High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center

Post-COVID interstitial lung disease in symptomatic patients after COVID-19 disease

COVID-19-induced neurological symptoms: focus on the role of metal ions

Ferulic acid attenuates pancreaticobiliary duct occlusion-induced inflammation in both pancreas and liver